RP1 + Opdivo, anti-PD1 failed NSCLC initial data
RP1 + Opdivo, anti-PD1 failed CSCC initial data
RP1 single agent initial data in CSCC transplant patients
RP2 + Opdivo initial data in all comers study
RP3 Phase 1 initial single agent data in all comers
Additional updates from all ongoing studies from which initial data has previously been released.
Next year;
CERPASS (CSCC registration directed trial) primary readout
IGNYTE (anti-PD1 failed melanoma registration directed trial) primary readout
RP3 + Opdivo data in all comers study
Potential for initial readouts from other follow on studies with RP2/3.
Recent REPL News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2024 12:36:13 PM
- Replimune Announces $100 Million Private Placement Financing • GlobeNewswire Inc. • 06/13/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2024 12:30:11 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/07/2024 08:51:06 PM
- Replimune to Present at the Goldman Sachs 45th Annual Global Healthcare Conference • GlobeNewswire Inc. • 06/07/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 01:15:41 PM
- Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma • GlobeNewswire Inc. • 06/06/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 01:27:39 PM
- Replimune Presents Positive Data from RP1 and RP2 Clinical Programs at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting • GlobeNewswire Inc. • 06/03/2024 12:00:00 PM
- Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting • GlobeNewswire Inc. • 05/23/2024 09:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/23/2024 08:17:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 12:06:59 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 12:06:11 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 12:01:55 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 12:00:21 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 05/16/2024 01:10:34 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 05/16/2024 01:07:28 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 05/16/2024 12:14:19 PM
- Form POSASR - Post-effective Amendment to an automatic shelf registration statement • Edgar (US Regulatory) • 05/16/2024 12:11:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/16/2024 12:08:47 PM
- Replimune Reports Fiscal Fourth Quarter and Year Ended 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 05/16/2024 12:00:00 PM
- Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting • GlobeNewswire Inc. • 04/07/2024 09:00:00 PM
- Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/04/2024 12:00:00 PM
- Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions • GlobeNewswire Inc. • 03/26/2024 11:30:00 AM
- Replimune to Present at the American Association for Cancer Research Annual Meeting 2024 • GlobeNewswire Inc. • 03/06/2024 01:00:00 PM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM